Kabergolin

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of cabergoline have been found .

Effects

A clinical trial studying sex differences in presentation and response to cabergoline therapy in patients with newly diagnosed hyperprolactinemia, found that successful response to carbergoline treatment for 6 months was similar in women and men. Prolactin levels normalized more frequently in micro- than in macroadenoma patients (86% vs. 64%), without a sex difference (70% vs. 69%, p=0.9). The sizes of macro- and microprolactinomas were reduced by 38 ±29% to 52 ±24%, and there was no difference in the amount of tumor shrinkage between men and women [1]. In another clinical study of carbergoline treatment in patients with hyperprolactinemia, men had less likelihood of achieving normal prolactin levels than women (75% vs. 90%). However, considered that the large majority of men had a macroprolactinoma (86% vs. 38% for women), which correlates with higher prolactin levels, sex had no independent influence on success rates. When only microprolactinomas were considered, the outcome was similar in men and women (92% vs. 93%) [2].

Adverse effects

Another clinical trial found no significant differences in prevalence of tricuspid regurgitation at any valve between hyperprolatinaemic men and women receiving carbergoline [3].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).